drugset / Trial / NCT04543955
Telotristat With Lutathera in Neuroendocrine Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial will test the hypothesis that Telotristat treatment increases the antitumor efficacy of Lutetium Lu 177 Dotatate therapy in neuroendocrine tumors (NETs).
Timeline
- Start
- 2021-09-13
- Primary completion
- 2022-06-03
- Completion
- 2022-06-03
Outcome
Outcome not reported
Stopped: “Sponsor cancelled research”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telotristat | Small molecule | 250 mg | Oral |
| Subject | Telotristat | Small molecule | 500 mg | Oral |
| Background | Lutetium Lu 177 Dotate | Unknown | — | Intravenous |